Atripla (tenofovir/emtricitabine/efavirenz) Coupons and Discounts
Atripla (tenofovir/emtricitabine/efavirenz) is a drug based on three antiretroviral drugs for the treatment of HIV/AIDS in adults. One way to save money on the Atripla (tenofovir/emtricitabine/efavirenz) retail cost regardless of income and insurance status is to use Atripla (tenofovir/emtricitabine/efavirenz) coupons or discount cards from RXCoupons. Use our Atripla (tenofovir/emtricitabine/efavirenz) coupons at your online pharmacy and receive up to 75% off the sale price each time you refill your prescription.
Atripla (tenofovir/emtricitabine/efavirenz) drug information
Atripla (tenofovir/emtricitabine/efavirenz) is a drug based on three antiretroviral drugs for the treatment of HIV/AIDS in adults. It is available in tablet form. Atripla contains efavirenz, emtricitabine and tenofovir disoproxil fumarate.
Atripla (tenofovir/emtricitabine/efavirenz) indications
Atripla (efavirenz/emtricitabine/tenofovir) is used as monotherapy or in combination with other antiretroviral agents for the treatment of HIV-1 in adults.
Atripla is contraindicated in patients with chronic hepatitis B. In addition, the drug can cause ketoacidosis and depression. Common side effects of Atripla include dizziness, headache, indigestion, nausea, vomiting, and allergic skin reactions.
Atripla (tenofovir/emtricitabine/efavirenz) contraindications
Atripla (efavirenz/emtricitabine/tenofovir) is contraindicated in patients with hypersensitivity to the drug and severe hepatic failure.
Dosage indications for Atripla (tenofovir/emtricitabine/efavirenz)
Note that Atripla (tenofovir/emtricitabine/efavirenz) therapy is not suitable for patients with prior treatment failure.
The recommended dose of Atripla for adults is 1 tablet 1 time per day. The tablet is swallowed whole, with water. Take on an empty stomach since food intake can lead to increased concentrations of efavirenz (adverse reactions can get worse). It is recommended to take the drug at bedtime (to improve the tolerability of efavirenz).
Atripla is not recommended for use in children, as there are no data on the efficacy and safety of the drug in this category of patients.
Atripla (tenofovir/emtricitabine/efavirenz) side effects
Patients may experience adverse reactions associated with individual components of Atripla (efavirenz/emtricitabine/tenofovir). The most common adverse reactions are diarrhea, nausea, headache, dizziness, depression, insomnia, sleep disorders and rash. Circulatory disorders: flushing, neutropenia, anemia. Respiratory system: shortness of breath, cough, pneumonia, rhinitis. Gastrointestinal tract: nausea, diarrhea, vomiting, abdominal pain, nausea, dyspepsia, flatulence and bloating, dry mouth. Rare: anorexia, acute pancreatitis, constipation, malabsorption. Renal dysfunction and urinary tract: renal failure, acute tubular necrosis, proximal tubulopathy, nephritis, acute nephritis, nephrogenic diabetes insipidus, proteinuria, polyuria. Skin and subcutaneous tissue: rash, redness, skin hyperpigmentation, dermatitis, edema. Uncommon reactions: dry skin, eczema, Stevens-Johnson syndrome, erythema multiforme. Musculoskeletal system: myopathy, osteomalacia, arthralgia, myalgia, back pain. General disorders: fatigue, fever, pain, asthenia, feeling of intoxication. Immune system: hypersensitivity, allergic reactions. Liver function: acute hepatitis, liver failure. Reproductive system: gynecomastia. Nervous system: dizziness, headache, sleep disturbance, drowsiness, insomnia, stupor, attention disorders, lethargy, seizures, visual disturbances, amnesia, ataxia, taste disturbance, agitation, hypoesthesia, paresthesia, neuropathy, tremor. Psychoneurotic violations: nightmares, depression, insomnia, anxiety, sleep disturbance, agitation, delirium, disorientation, aggression, neurosis, suicide attempts, mania, hallucinations. Atripla overdose may cause involuntary muscle contractions.
Atripla (tenofovir/emtricitabine/efavirenz) during pregnancy or breastfeeding
Atripla (efavirenz/emtricitabine/tenofovir) should not be used during pregnancy. Women of childbearing age should use barrier methods of contraception while taking the drug. Women of childbearing age should take a pregnancy test before starting Atripla therapy.
Since there is a double risk of transmission of HIV, mothers should stop breastfeeding during Atripla therapy.
Atripla (tenofovir/emtricitabine/efavirenz) cautions
Atripla (tenofovir/emtricitabine/efavirenz) should not be used together with other drugs containing efavirenz, emtricitabine or tenofovir. The drug should not be administered simultaneously with lamivudine.
The drug should be used with caution in elderly patients (high risk of hepatic disorders in these patients). It should be used with caution in any patient (particularly women who are overweight) who has hepatomegaly, hepatitis or steatosis (associated with certain drugs and alcohol).
Patients who are at high risk should be under special control.
Atripla or other antiretroviral drugs may be associated with the development of opportunistic infections. The constant presence of the supervising physician (experienced in the treatment of patients with HIV-related infections) is required.